NRX Pharmaceuticals, Inc.
For the period ended Jan 12, 2026. Filed Jan 16, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 12, 2026 · Filed Jan 16, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · PROXY STATEMENT
proxy statement for the 2025 Annual Meeting to be filed with the U.S. Securities and Exchange Commission (the “SEC”) prior to the 2025 Annual Meeting.
Because the date of the 2025 Annual Meeting is more than 60 days after the anniversary of the Company’s prior annual meeting held on October 8, 2024 (the “2024 Annual Meeting”), the deadline for stockholder nominations or proposals for consideration at the 2025 Annual Meeting set forth in the Company’s 2024 proxy statement no longer applies. As such, the Company would like to publicly announce the date of the 2025 Annual Meeting and provide the due date for the submission of any qualified
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.